Daiichi Sankyo takes Europe by storm with new cancer strategy

With a plan to get 7 drugs approved in 8 years, Daiichi Sankyo is very busy. Success requires a big shake up in Europe, including the Nordics, says development director Gilles Galllant.

"At the moment we are following a course where we add one person to the Nordic organization every month," says Patrik Grandits. Photo: Daiichi Sankyo / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles